Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Biogen Clear all
Completed Phase 1 Interventional

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

NCT00618735
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BIIB021
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Encinitas, California • Santa Monica, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

NCT02036970
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
Interventions
Bardoxolone methyl, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion Study of BIIB074

NCT02751905
View directory record Official record
Conditions
Neuropathic Pain
Interventions
BIIB074
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 16, 2026, 10:43 PM EDT
Completed No phase listed Observational

A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits

NCT02778438
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Quintiles, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

NCT01518920
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
PF-04958242, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Anaheim, California • New Haven, Connecticut • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 4 Interventional

A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

NCT04488133
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Months to 36 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 16, 2026, 10:43 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122 225 mg, BIIB122-Matching Placebo
Drug · Other
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

NCT02133924
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
natalizumab, steroids
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 16, 2026, 10:43 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging

NCT05058950
View directory record Official record
Conditions
Mild Cognitive Impairment, Normal Aging
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 86 Years
Enrollment
22,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy

NCT01703988
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 15 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 3 Interventional

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

NCT00660959
View directory record Official record
Conditions
Hyponatremia With Normal Extracellular Fluid Volume
Interventions
lixivaptan, placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

NCT02459886
View directory record Official record
Conditions
Parkinson's Disease, Healthy
Interventions
BIIB054, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

NCT02269930
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
peginterferon beta-1a, Rebif
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 16, 2026, 10:43 PM EDT
Completed No phase listed Observational

Pregnancy Exposure Registry for Tysabri®

NCT00472992
View directory record Official record
Conditions
Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 16, 2026, 10:43 PM EDT
Terminated Phase 3 Interventional Results available

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02477800
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
59
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia

NCT02917187
View directory record Official record
Conditions
Primary Inherited Erythromelalgia
Interventions
BIIB074, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Birmingham, Alabama • New London, Connecticut • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 16, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

NCT05160558
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 3
Interventions
BIIB132, BIIB132-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 16, 2026, 10:43 PM EDT
Terminated Phase 1 Interventional

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

NCT02658916
View directory record Official record
Conditions
Supranuclear Palsy, Progressive
Interventions
BIIB092
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Natalizumab Re-Initiation of Dosing

NCT00306592
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BG00002 (natalizumab)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

NCT00000721
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

NCT03672175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
53
States / cities
Rogers, Arkansas • Bellflower, California • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers

NCT02171208
View directory record Official record
Conditions
Healthy
Interventions
dimethyl fumarate - Reference form, dimethyl fumarate - Test form
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 16, 2026, 10:43 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

NCT04241068
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
104
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 16, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

NCT00119730
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Fludarabine, Mitoxantrone, Rituximab, Zevalin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 16, 2026, 10:43 PM EDT